

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 02-1019-A1)

In the Application of:)	
)	
Raepfel et al.)	
)	International Appl. No.:
Serial No.: TBA)	PCT/CA03/001557
)	
)	International Filing
Filed: Herewith)	Date: October 16, 2003
)	
For: Inhibitors of Histone Deacetylase)	

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. The references are listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449 may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this statement or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

Also, enclosed is a copy of the International Search Report in which some of the above-listed references were cited during the prosecution of a corresponding PCT application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

By: Raafat M. Shaltout
Raafat M. Shaltout
Reg. No. 45,092
McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, Suite 3100
Chicago, Illinois 60606

Dated: April 14, 2005

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		02-1019-A1	To Be Assigned
		10/531406	
		Applicant:	
		Raepel et al.	
		Filing Date:	Group:
		Herewith	To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
------------------	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
A1	EP 0 847 992 A1	06/17/1998	EP				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

A2	Weidle, U. H.; Grossmann, A., "XP-001098720 – Inhibition of Histone Deacetylases: a New Strategy to Target Epigenetic Modifications for Anticancer Treatment", <i>Anticancer Research</i> 20, 2000, pp. 1471-1486.
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.